Clinical trials: Itching Symptoms
- Condition Itching Symptoms
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Tinea Pedis
Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to…
- Trial name
- NCT00835510
- Testing
- Butenafine cream 1% manufactured by Taro, Lotrimin Ultra (butenafine) 1%, Butenafine Vehicle manufactured by Taro
- Where
- 17 sites in United States, Belize
- Volunteers
- 548 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis, Tinea Cruris
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence…
- Conditions
- Tinea Pedis, Tinea Cruris, Tinea Corporis
- Trial name
- NCT01349998
- Testing
- Product 33525
- Where
- 24 sites in United States, Belize and 3 more
- Volunteers
- 604 people
- Sponsor
- Tinea Pharmaceuticals
Atopic Dermatitis
Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older
This is a double-blind, randomized, vehicle-controlled, multi-center, parallel group Phase 3 study of MSRD-100 in the treatment of atopic dermatitis in subjects aged 3 months and up
- Trial name
- MSRD-100 (NCT02677636)
- Testing
- MSRD-100, Vehicle
- Sponsor
- Merz North America, Inc.
Atopic Dermatitis
Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis
Atopic dermatitis (AD) is a common skin disease that has increased in prevalence worldwide two- to threefold over the last 50 years.
- Trial name
- NCT00460083
- Testing
- Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Ceragenix Pharmaceuticals
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Pregnancy Related, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
- Trial name
- NCT06627335
- Testing
- Ruxolitinib Cream, TCS
- Where
- United States
- Volunteers
- 5,621 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Efficacy Emollient on Xerosis in Children With Atopic Dermatitis
Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local, immunological, genetic and environmental factors.
- Trial name
- NCT01467362
- Testing
- V0034CR01B, Vehicle cream, desonide 0.1% cream
- Where
- 25 sites in Estonia, France and 3 more
- Volunteers
- 251 people
- Sponsor
- Pierre Fabre Medicament
Rhinitis
Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics
To evaluate the safety of treatment with levocetirizine oral solution in pediatric patients aged form 6 months to 2 years old with allergic rhinitis or pruritus associated with the skin diseases.
- Trial name
- NCT01563081
- Testing
- Levocetirizine
- Where
- 7 sites in Japan
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Tinea Pedis
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
The objective of this study is to demonstrate that Oxiconazole nitrate 1% topical cream is effective for the treatment of patients with moderate to severe Tinea pedis.
- Trial name
- NCT01519752
- Testing
- Oxiconazole Nitrate Cream 1%, Oxiconazole Nitrate Cream 1% (Oxistat®)
- Volunteers
- 661 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alagille Syndrome
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
An open-label, single-arm, multi-centre program providing treatment access to ALGS patients with cholestatic pruritus in the US.
- Trial name
- NCT04530994
- Testing
- maralixibat
- Where
- 14 sites in United States
- Sponsor
- Mirum Pharmaceuticals, Inc.
Eczema, Allergy Symptoms
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who…
- Conditions
- Eczema, Allergy Symptoms, Psoriasis, Itch
- Trial name
- NCT02075632
- Testing
- Alclometasone dipropionate cream
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Tinea Pedis
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
- Trial name
- NAFT-600 (NCT01290341)
- Testing
- NAFT-600 (naftin 2 % gel)
- Where
- 23 sites in United States
- Volunteers
- 860 people
- Sponsor
- Merz North America, Inc.
Epidermolysis Bullosa (EB)
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry.
- Trial name
- NCT07482787
- Testing
- SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Paradigm Therapeutics
Tinea Pedis, Athlete's Foot
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).
- Trial name
- NCT00750139
- Testing
- NAFT-500, Naftin 1%
- Where
- 17 sites in United States
- Volunteers
- 707 people, healthy volunteers welcome
- Sponsor
- Merz North America, Inc.
Seasonal Allergic Rhinitis
A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis
You are being asked to take part in a research study of COLD-fX, a product designed to boost the immune system. COLD-fX is an extract from the roots of North American ginseng and it may offer some benefit to people with seasonal…
- Trial name
- NCT00726401
- Testing
- COLD-fX
- Where
- 4 sites in Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Afexa Life Sciences Inc
Fungal Infections, Tinea Pedis
Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections
This is a study clinical, multicenter, Phase III trial, to evaluate the efficacy and safety of tolnaftate cream in the treatment of patients with fungal infections such as Tinea foot, Tinea and Tinea crural body.
- Conditions
- Fungal Infections, Tinea Pedis, Tinea Cruris, Tinea Corporis
- Trial name
- Tonaftato (NCT01105013)
- Testing
- Clotrimazole
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Laboratório Teuto Brasileiro S/A
Atopic Dermatitis
A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis
This is a Phase II, multi-centre, randomised, double-blind, placebo-controlled study in male and female subjects, aged ≥ 12 years with mild/moderate atopic dermatitis and at least moderate pruritus.
- Trial name
- NCT01808157
- Testing
- CT327 ointment
- Where
- United Kingdom
- Volunteers
- 188 people
- Sponsor
- Creabilis SA
Atopic Dermatitis
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.
- Trial name
- NCT04605094
- Testing
- Benralizumab
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 194 people
- Sponsor
- AstraZeneca
Pruritus
Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics
To assess the safety of long-term use of cetirizine dry syrup in children with various type of cutaneous disease accompanied on pruritus.
- Trial name
- NCT00257582
- Testing
- Cetirizine Dry Syrup
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline